CAR-T Therapy Shows Durable Benefits in Myasthenia Gravis

(MedPage Today) -- Mivocabtagene autoleucel (miv-cel), an autologous CD19 chimeric antigen receptor (CAR)-T cell therapy, showed benefits lasting 6 months or longer for generalized myasthenia gravis patients in the phase II portion of the KYSA...